Why the study?
Does low-dose IGF-I therapy improve VLDL apoB metabolism in patients with type 1 diabetes?
Does low-dose IGF-I therapy improve VLDL apoB metabolism in patients with type 1 diabetes?
Low-dose IGF-I therapy in type 1 diabetes improves fasting triglyceride concentrations and VLDL composition, likely by increasing insulin sensitivity, though it does not significantly alter VLDL apoB kinetics.
No takes yet. Share an insight, caveat, or question.
Low-dose IGF-I improves triglycerides and VLDL composition in T1D; extends evidence for its metabolic effects beyond glucose control.
Christ et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: